Nathan Evans is a registered patent attorney with Woods Rogers who focuses on intellectual property (IP)—including patents, copyrights, trademarks, trade secrets, and antitrust issues—and he assists start-ups and established companies protect and monetize their IP rights.
Based in Charlottesville, Nathan counsels clients in virtually all IP-related topics, including patent preparation and prosecution, opinions, enforcement strategies, litigation, and licensing. He has worked on matters before state and federal district courts, the U.S. International Trade Commission, and the Court of Appeals for the Federal Circuit.
Nathan’s trial experience includes cases involving the infringement, validity, and enforceability of patents covering AstraZeneca’s Crestor and Eli Lilly’s Zyprexa. In addition to litigation regarding chemical compounds and biotechnology, he has participated in matters involving computer software applications, networking solutions, cellular phone technology, multilayer plastic films, paper products, pultruded and extruded structural articles, and optical discs (CDs).
Nathan has substantial experience with India’s patent laws and co-chaired an American Bar Association subcommittee on changes to Indian patent law. He also acted as a co-chair of a subcommittee of the Patent System Policy Planning Division Committee.
His experience highlights include:
- Successfully argued patent claim construction issues in favorable Markman ruling (W.D. Va. Feb. 4, 2015)
- Successfully helped defend lucrative electrical engineering patent and license in significant jury trial victory (S.D.N.Y. 2013)
- In re Rosuvastatin Calcium Patent Litigation (D. Del.). Helped successfully obtain determination of infringement, validity, and enforceability of an Orange Book listed patent for AstraZeneca over the drug product Crestor®
- Eli Lilly & Co. v. Zenith Goldline Pharms., Inc. (S.D. Ind., Fed. Cir.). Helped successfully obtain determination of infringement, validity, and enforceability of an Orange Book listed patent for Eli Lilly over the drug product Zyprexa®
- Active in other successful Abbreviated New Drug Application (ANDA) patent infringement litigations defending challenges to pharmaceutical patents, including patents on Eli Lilly and Company’s Evista® pharmaceutical
- Held leadership roles at the American Bar Association, co-chairing subcommittees regarding compulsory licensing issues and changes to India’s patent law regime
- Represented on a pro bono basis environmental groups, underprivileged defendants, and a political asylum applicant, usually acting as lead counsel
Nathan double-majored in biology and psychology at the University of Virginia before entering law school. He writes and speaks on various topics, including IP issues generally, patent laws in India, and prescription drug licensing. He joined the Woods Rogers Charlottesville office in 2013.
- District of Columbia Bar
- Virginia State Bar
- U.S Patent and Trademark Office
- U.S. Court of Appeals, Federal Circuit
- U.S. Court of Appeals, Fourth Circuit
- Emory University School of Law, J.D., 2001
- University of Virginia, B.A., 1998